Adverse cutaneous reactions to the new second-generation tyrosine kinase inhibitors (dasatinib, nilotinib) in chronic myeloid leukemia
- 1 November 2013
- journal article
- Published by Elsevier BV in Journal of the American Academy of Dermatology
- Vol. 69 (5), 839-840
- https://doi.org/10.1016/j.jaad.2013.07.025
Abstract
No abstract availableKeywords
This publication has 5 references indexed in Scilit:
- Cutaneous Drug Eruptions Associated with the Use of New Oncological DrugsPublished by S. Karger AG ,2012
- Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up resultsBlood, 2011
- Dasatinib in imatinib‐resistant or imatinib‐intolerant chronic myeloid leukemia in blast phase after 2 years of follow‐up in a phase 3 studyCancer, 2010
- Dasatinib inhibits site-specific tyrosine phosphorylation of androgen receptor by Ack1 and Src kinasesOncogene, 2010
- Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: A prospective study of 54 patientsJournal of the American Academy of Dermatology, 2003